Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis

Internal Medicine

Volumn 51, Issue 10, 2012, Pages 1177-1182

  Liu, Ban ^a   Zhang, Jian Ying ^b   Cao, Hua Ming ^c   Wang, Qiang ^c   Wang, Hong Bao ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cholesterol; Endothelial; Inflammation atherosclerosis; Rho; Rho kinase; Rosuvastatin

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOSIN; RHO KINASE; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; ASIAN; ATHEROSCLEROSIS; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; EVENING DOSAGE; FEMALE; HUMAN; INFLAMMATION; LOW DRUG DOSE; MALE; RANDOMIZED CONTROLLED TRIAL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINES; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; SULFONAMIDES; VASODILATION;

EID: 84861758609     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6771     Document Type: Article

References (33)

1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115: 1285-1295, 2007.
2. Pirro M, Schillaci G, Romagno PF, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J Cardiovasc Pharmacol Ther 14: 14-21, 2009.
3. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
4. Baigent CA, Keech PM, Kearney L, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366: 1267-1278, 2005.
5. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001.
6. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 11: 2295-2322, 1997.
7. Liu PY, Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rhoassociated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119: 131-138, 2009.
8. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
9. Bolz SS, Vogel L, Sollinger D, et al. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation 107: 3081-3087, 2003.
10. Ito T, Ikeda U, Shimpo M, et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther 16: 121-126, 2002.
11. Mabuchi H, Nohara A, Higashikata T, et al. Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 11: 152-158, 2004.
12. Saito Y, Yamada N, Shirai K, et al. Effect of rosuvastatin 5-20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. Atherosclerosis 194: 505-511, 2007.
13. Rawlings R, Nohria A, Liu PY, et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on Rho kinase activity in Caucasian men with a previous atherosclerotic event. Am J Cardiol 103: 437-441, 2009.
14. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannosebinding protein in human serum. Ann Clin Biochem 35: 745-753, 1998.
15. Nohria A, Prsic A, Liu PY, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205: 517-521, 2009.
16. Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosinbinding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 147: 1023-1038, 1999.
17. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 23: 7-17, 2005.
18. Saito Y, Goto Y, Dane A, Strutt K, Raza A. Randomized doseresponse study of Rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 10: 329-336, 2003.
19. Schneck DW, Knopp RH, Ballantyne CM, et al. Comparative effects of Rosuvastatin and Atorvastatin across their dose range in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 91: 33-41, 2003.
20. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109: 39-43, 2004.
21. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for "pleiotropic" functions of statin therapy. Eur Heart J 27: 1182-1190, 2006.
22. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 49: 1035-1042, 2007.
23. Pasterkamp G, van Lammeren GW. Pleiotropic effects of statins in atherosclerotic disease. Cardiovasc Ther 8: 1235-1237, 2010.
24. Liao JK. Rho-kinase: a potential link between hypercholesterolemia and abnormal vascular smooth muscle contraction. Circ Res 99: 238-239, 2006.
25. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998.
26. Noma K, Rikitake Y, Oyama N, et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 118: 1632-1644, 2008.
27. Horwitz AR, Parsons JT. Cell migration-movin' on. Science 286: 1102-1103, 1999.
28. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106: 57-62, 2002.
29. Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 22: 8467-8477, 2002.
30. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
31. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107: 370-371, 2003.
32. Nakakuki T, Ito M, Iwasaki H, et al. Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 25: 2088-2093, 2005.
33. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207, 2008.